rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Peripheral NOP receptor activation reduces CGRP-induced migraine pain as effectively as brain-penetrant treatment

RPEP-136912025Sturaro, Chiara; Pola, Pietro; Argentieri, Michela; Frezza, Alessia; Marini, Matilde; De Logu, Francesco; Albanese, Valentina; Soukupova, Marie; Malfacini, Davide; Zaveri, Nurulain T; Nassini, Romina; Jensen, Dane D; Geppetti, Pierangelo; Calò, Girolamo; Ruzza, Chiara
evidence
The takeaway

A peripherally restricted NOP agonist (UFP-112) reduced CGRP-evoked periorbital allodynia equally to a brain-penetrant NOP agonist (AT-403) in mice, with N/OFQ inhibiting CGRP-induced cAMP in human Schwann cells—suggesting peripheral NOP targeting as a migraine strategy.

Peripheral NOP = brain-penetrant

A peripherally restricted NOP agonist matched the brain-penetrant compound for CGRP pain relief—enabling safer migraine treatment without CNS side effects

What the researchers found

UFP-112 (peripheral) = AT-403 (brain-penetrant) for reducing CGRP-evoked PMA. N/OFQ internalized NOP and recruited Gαi at membrane + endosomes. N/OFQ attenuated CGRP-induced cAMP in human Schwann cells. NOP knockout: no baseline difference in CGRP sensitivity.

Why it matters

Peripheral-only NOP agonists could provide migraine relief without CNS side effects. The identification of Schwann cells as the cellular target bridges neuropeptide pharmacology with peripheral nerve biology.

How the study worked

CGRP-induced PMA in wild-type, NOP-/-, and CD-1 mice. NOP agonists (AT-403, UFP-112). HEK293 NOP signaling studies. Human Schwann cell cAMP assays.

What this study cannot tell us

Mouse model. Schwann cell as cellular site needs in vivo confirmation. UFP-112 pharmacokinetics in humans unknown. Single pain model tested.

How to read the evidence

Preclinical with in vivo pain model and in vitro mechanistic studies in human cells. Good translational evidence.

When this study was published

Published in 2025.

The bigger picture

The NOP system represents a novel migraine target complementary to CGRP blockade. Peripheral NOP agonists could be developed as safe, effective migraine treatments without the CNS side effects that limit current analgesics.

Questions still open

  • Could NOP agonists be combined with anti-CGRP drugs for refractory migraine?
  • Would NOP agonists help patients who do not respond to CGRP-targeting therapies?
  • Are there other peripheral cell types where NOP-CGRP interaction is important?

Common questions

What is the NOP receptor system?
The NOP (nociceptin/orphanin FQ) receptor is part of the opioid receptor family but does not respond to traditional opioid drugs. This study shows activating NOP receptors in peripheral nerves can counteract CGRP-induced migraine pain, offering a non-opioid approach to pain relief.
Why is peripheral-only treatment important?
Drugs that only work outside the brain avoid CNS side effects like sedation and cognitive impairment. This study proves that activating NOP receptors only in peripheral nerves (not the brain) is enough to relieve CGRP-induced migraine pain, enabling development of safer migraine drugs.

Read the original research

Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice.

British journal of pharmacology

View on PubMed ↗Publisher’s paper ↗

Citation

Sturaro, Chiara; Pola, Pietro; Argentieri, Michela; Frezza, Alessia; Marini, Matilde; De Logu, Francesco; Albanese, Valentina; Soukupova, Marie; Malfacini, Davide; Zaveri, Nurulain T; Nassini, Romina; Jensen, Dane D; Geppetti, Pierangelo; Calò, Girolamo; Ruzza, Chiara. (2025). Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice.. British journal of pharmacology. https://doi.org/10.1111/bph.70162